ASX - Delayed Quote AUD

Pacific Edge Limited (PEB.AX)

0.0700 -0.0090 (-11.39%)
At close: April 26 at 4:10 PM GMT+10

Key Executives

Amounts are as of December 31, 2009 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
NameTitlePayExercisedYear Born
Dr. Peter Meintjes Chief Executive Officer -- -- --
Mr. Grant Gibson Chief Financial Officer -- -- --
Mr. Darrell Morgan Chief Operating Officer -- -- --
Dr. Justin Harvey Chief Technology Officer -- -- --
Prof. Parry Guilford Ph.D. Chief Scientific Officer & Member of Scientific Advisory Board 122.38k -- --
Mr. Jack Atchason Senior Vice President of Sales - Pacific Edge Diagnostics USA Limited -- -- --
Mr. Andrew McIntosh Chief Digital Officer -- -- --
Glen Costin President of Asia Pacific -- -- --
Dr. Tamer Aboushwareb Chief Medical Officer -- -- --
Mr. David Levison Executive Chairman & President of Pacific Edge Diagnostics USA 48.41k -- 1960

Pacific Edge Limited

Centre for Innovation
87 St David Street PO Box 56
Dunedin, 9016
New Zealand
64 3 479 5800 https://www.pacificedgedx.com
Sector: 
Healthcare
Full Time Employees: 
114

Description

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. The company operates in two segments, Commercial and Research. It offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. The company is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, it is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Corporate Governance

Pacific Edge Limited’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 6; Board: 2; Shareholder Rights: 7; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers